What;s wrong with their Math? I caculate about 40% rise in the last four months,These ZACK reports use simple algoritihims that don't take a lot of data into consideration, meaning they are useless-especially in the world of biotechs but knee-jerk investors might get shook out. Classic.
This is the problem when you invest too early. Should always wait until late Phase 2. That way, you'll avoid getting hammered from reverse splits and dilution. I bet the share count will get to where it was before the RS. That's the game folks. NBS needs money to fund trials and will need more and more in the future. After the dilution, share price falls eventually to the point where there is another RS and the game goes on and on. I may be a buyer of this company someday but it is way too early. Good luck to all!